Relay Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Claire Mazumdar, Ph.D.

Relay Therapeutics, Inc.’s own tally for this item (“Elect Director: Claire Mazumdar, Ph.D.”): 122,859,060 for, 24,196,764 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected each of the following individuals to serve as class III directors for a three-year term ending at the Company's 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignat…”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 30,448,767 for, 4,594,664 withheld, 64 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Douglas S. Ingram

Relay Therapeutics, Inc.’s own tally for this item (“Elect Director: Douglas S. Ingram”): 120,859,999 for, 26,195,825 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected each of the following individuals to serve as class III directors for a three-year term ending at the Company's 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignat…”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 29,968,690 for, 5,074,739 withheld, 65 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: To approve an amendment to our Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 300,000,000 to 450,000,000; and

Relay Therapeutics, Inc.’s own tally for this item (“4. Approval of amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended”): 170,323,683 for, 909,020 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 300,000,000 shares to 450,000,000 shares, with the votes cast as follows:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 35,027,709 for, 15,786 against.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: To consider and act upon an advisory vote on the compensation of our named executive officers;

Relay Therapeutics, Inc.’s own tally for this item (“2. Non-binding advisory vote on executive compensation”): 143,849,919 for, 3,154,118 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, with the votes cast as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 65 managers: 34,121,388 for, 912,712 against, 8,985 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 179 managers: 110,180,388 for, 2,302,722 against, 525,073 withheld, 68 abstained, 3,556 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

Relay Therapeutics, Inc.’s own tally for this item (“3. Ratification of appointment of independent registered public accounting firm”): 171,030,133 for, 204,449 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 35,034,394 for, 116 against, 8,985 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.